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ABSTRACT
Background Coronary artery bypass graft (CABG) patients 
are under- represented in acute coronary syndrome (ACS) 
trials. We compared characteristics and outcomes for 
patients who did and did not participate in a randomised 
trial of invasive versus non- invasive management (CABG- 
ACS).
Methods ACS patients with prior CABG in four hospitals 
were randomised to invasive or non- invasive management. 
Non- randomised patients entered a registry. Primary 
efficacy (composite of all- cause mortality, rehospitalisation 
for refractory ischaemia/angina, myocardial infarction (MI), 
heart failure) and safety outcomes (composite of bleeding, 
stroke, procedure- related MI, worsening renal function) 
were independently adjudicated.
Results Of 217 patients screened, 84 (39%) screenfailed, 
of whom 24 (29%) did not consent and 60 (71%) were 
ineligible. Of 133 (61%) eligible, 60 (mean±SD age, 
71±9 years, 72% male) entered the trial and 73 (age, 
72±10 years, 73% male) entered a registry (preferences: 
physician (79%), patient (38%), both (21%)).
Compared with trial participants, registry patients had 
more valve disease, lower haemoglobin, worse New York 
Heart Association class and higher frailty.
At baseline, invasive management was performed in 52% 
and 49% trial and registry patients, respectively, of whom 
32% and 36% had percutaneous coronary intervention at 
baseline, respectively (p=0.800). After 2 years follow- up 
(694 (median, IQR 558–841) days), primary efficacy (43% 
trial vs 49% registry (HR 1.14, 95% CI 0.69 to 1.89)) and 
safety outcomes (28% trial vs 22% registry (HR 0.74, 
95% CI 0.37 to 1.46)) were similar. EuroQol was lower in 
registry patients at 1 year.
Conclusions Compared with trial participants, registry 
participants had excess morbidity, but longer- term 
outcomes were similar.
Trial registration number NCT01895751.
INTRODUCTION
Coronary artery bypass graft (CABG) surgery 
is standard of care for patients with obstructive 
coronary artery disease. However, occlusive 
disease of saphenous vein grafts is common 
within 10 years of surgery,1–3 meaning patients 
with prior CABG have a progressive longer- 
term risk of recurrent ischaemia, including 
angina and myocardial infarction (MI), heart 
failure (HF) and death. Given the large 
number of CABG recipients living globally, and 
their health complexities, including increasing 
age and multimorbidity, this represents an 
increasing healthcare challenge globally, 
Key questions
What is already known about this subject?
 ► Pivotal clinical trials of invasive management versus 
non- invasive medical management in acute coro-
nary syndromes (ACS) excluded patients with prior 
coronary artery bypass graft (CABG).
What does this study add?
 ► The CABG- ACS trial and registry provides novel, con-
temporary insights into an understudied subgroup of 
ACS patients with a substantial health burden.
How might this impact on clinical practice?
 ► The CABG- ACS pilot trial and registry fills in an evi-
dence gap on the natural history and optimal treat-
ment strategy for this comparatively large subgroup 
of patients. Furthermore, the CABG- ACS trial and 
registry may be helpful in the design of clinical trials 
in this patient group.  on M
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not least because of rehospitalisation due to recurrent 
ischaemia.4 5 Chest pain is the most common reason for 
hospital admission in the UK and about 1 in 10–15 patients 
admitted to hospital with an acute non- ST segment eleva-
tion acute coronary syndrome (NSTE- ACS) have a prior 
CABG.6
Pivotal clinical trials comparing routine invasive manage-
ment vs conservative non- invasive management in unstable 
coronary syndromes excluded patients with prior CABG 
(online supplemental table 1). Current guidelines recom-
mend a routine early invasive strategy in higher risk 
NSTE- ACS patients.7–9 However, invasive management 
is performed less often in NSTE- ACS patients with prior 
CABG, probably because the risk:benefit balance is consid-
ered to be less favourable in these patients compared with 
those without prior CABG.10–12 Furthermore, when inva-
sive management is performed, percutaneous coronary 
intervention (PCI) is less likely in prior CABG patients,11–13 
implying a lower likelihood of benefit with a routine inva-
sive strategy. Real- world evidence implies clinical practice 
departs from the results of systematic reviews and guide-
lines,14 15 indicating physician and patient preferences for 
treatment options may be relevant. Overall, evidence is 
lacking to inform the validity of current guideline recom-
mendations,7–9 in NSTE- ACS patients with prior CABG. 
This important subgroup of ACS patients remains compar-
atively understudied. Enrolment into randomised trials 
can be challenging,16 particularly when the intervention 
disrupts standard care. Enrolment of elderly patients may 
be challenging, sometimes leading to premature trial 
discontinuation.17–19
We hypothesised that the clinical characteristics, 
treatment and health outcomes would differ between 
participants enrolled in a randomised controlled trial of 
routine invasive versus routine non- invasive management 
in NSTE- ACS patients with prior CABG, and participants 
enrolled in the registry due to physician and/or patient 
preference. We aimed to prospectively gather informa-
tion on the trial and registry participants in order to gain 
contemporary information on the natural history and 
reasons for trial participation or not.
METHODS
We undertook a randomised controlled trial of routine 
invasive management vs routine conservative manage-
ment in NSTE- ACS patients with prior CABG. Concur-
rently, patients who were ineligible for randomisation 
and who gave informed consent were entered into an 
observational registry. The study design,20 and results of 
the main trial have been published.21
Study population
Inclusion criteria were: (1) unstable angina or non- ST 
segment elevation MI; (2) stabilised symptoms without 
recurrent chest pain or intravenous therapy for 12 hours 
and (3) prior CABG.
Exclusion criteria were: (1) refractory ischaemia (ie, 
recurrent angina with minimal exertion or at rest (ie, 
Canadian Cardiovascular Society (CCS) class III or IV) 
not controlled by medical therapy); (2) cardiogenic 
shock; (3) lack of informed consent and (4) unsuitable 
for invasive management.
Randomisation
Patients fulfilling inclusion criteria without any exclusion 
criteria who consented to participate in the randomised 
trial were enrolled (figure 1). Randomisation was 
performed by the Trials Unit interactive voice recogni-
tion system to one of two groups: initial medical manage-
ment or initial invasive management (online supple-
mental methods).
Registry
Information was prospectively recorded in a registry for 
acute NSTE- ACS and prior CABG patients who were not 
randomised but consented to participate in the registry. 
Reasons for non- participation in the randomised trial 
were prospectively recorded: exclusion criteria present, 
unsuitability for either invasive or non- invasive manage-
ment, physician preference, patient preference or a 
combination of these factors. Baseline and follow- up 
clinical information were obtained similarly to the trial 
patients.
Figure 1 CONSORT diagram in CABG- ACS. CABG, 
coronary artery bypass graft; CONSORT, Consolidated 
Standards of Reporting Trials; NSTE- ACS, non- ST segment 
elevation acute coronary syndrome.
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  Age, years Mean±SD 71±10 71±9 72±10 0.46
  Female sex N (%) 37 (28) 17 (28) 20 (27) 1.00
  Obese (body mass index >30 kg/m2) N (%) 37 (28) 22 (37) 15 (21) 0.05
Presentation type*
  Non- ST segment elevation MI N (%) 90 (68) 41 (68) 49 (67) 1.00
  Unstable angina N (%) 43 (32) 19 (32) 24 (33) 1.00
Medical history
  Diabetes mellitus† N (%) 50 (38) 21 (35) 29 (40) 0.60
  Previous MI N (%) 91 (68) 41 (68) 50 (68) 1.00
  Cardiac arrhythmia N (%) 47 (36) 19 (32) 28 (39) 0.37
  Treated hypertension N (%) 88 (66) 42 (70) 46 (63) 0.46
  Renal impairment N (%) 38 (29) 13 (22) 25 (34) 0.13
  Peripheral vascular disease N (%) 32 (24) 16 (27) 16 (22) 0.55
  Cerebrovascular disease N (%) 30 (23) 13 (22) 17 (23) 0.84
  Congestive HF N (%) 44 (33) 14 (23) 30 (41) 0.04
  Anaemia N (%) 20 (15) 5 (8) 15 (21) 0.05
  Valve disease N (%) 43 (32) 12 (20) 31 (42) 0.01
  Pacemaker N (%) 11 (8) 5 (8) 6 (8) 1.00
  History of smoking
  Current N (%) 27 (20) 12 (20) 15 (21) 0.35
  Former (>3 months) N (%) 80 (60) 33 (55) 47 (64)
  Never N (%) 26 (20) 15 (25) 11 (15)
  Serum creatinine, μmol/L Median (IQR) 86 (71–114) 84 (68–101) 89 (73–131) 0.11
  Haemoglobin, g/L Mean±SD 131±18 135±16 127±18 0.01
  Charlson Comorbidity Index Median (IQR) 5 (3–7) 4 (3–6) 5 (3–7) 0.28
  Health- related quality of life, EuroQol 5 








ECG abnormalities at initial presentation
  ST- segment depression N (%) 67 (50) 28 (47) 39 (53) 0.49
  ST- segment elevation N (%) 27 (20) 11 (18) 16 (22) 0.67
  T- wave inversion N (%) 89 (67) 38 (63) 51 (70) 0.46
  Q- waves N (%) 42 (32) 15 (25) 27 (37) 0.19
  Left bundle branch block N (%) 11 (8) 5 (8) 6 (8) 1.00
  AF or flutter N (%) 23 (17) 9 (15) 14 (19) 0.65
  New ischaemic ECG changes‡ N (%) 66 (50) 30 (50) 36 (50) 1.00
Canadian Cardiovascular Society angina class§
  1 N (%) 4 (3) 2 (3) 2 (3) 0.83
  2 N (%) 11 (8) 6 (10) 5 (7)
  3 N (%) 26 (20) 10 (17) 16 (22)
  4 N (%) 90 (69) 41 (69) 49 (68)
New York Heart Association functional class
Continued
 on M
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Follow-Up
Follow- up (via telephone contact, clinic visits, letter) 
with completion of quality of life assessments (EuroQol 
Visual Analogue Scale (EQ- VAS) and EuroQol 5 Dimen-
sions 5 Levels (EQ- 5D- 5L)) was maintained 6 monthly 
until ≥18 months follow- up was reached for the final 
recruited patient (online supplemental methods).
Clinical event committee
An independent clinical event committee reviewed the 









  I N (%) 47 (35) 30 (50) 17 (23) 0.01
  II N (%) 47 (35) 18 (30) 29 (40)
  III N (%) 28 (21) 8 (13) 20 (27)
  IV N (%) 11 (8) 4 (7) 7 (10)
Coronary artery bypass grafts
  Left internal mammary artery N (%) 109 (82) 50 (83) 59 (81) 0.82
  No/unknown N (%) 24 (18) 10 (17) 14 (19)
  Saphenous vein graft
  0 N (%) 10 (8) 3 (5) 7 (10) 0.74
  1 N (%) 37 (29) 17 (29) 20 (29)
  2 N (%) 54 (43) 25 (43) 29 (43)
  ≥3 N (%) 25 (20) 13 (22) 12 (18)
Frailty index
  Fit or well (1,2,3) N (%) 60 (45) 35 (58) 25 (34) 0.03
  Vulnerable (4) or mildly frail (5) N (%) 42 (32) 14 (23) 28 (38)
  Moderately frail (6) N (%) 29 (22) 10 (17) 19 (26)
  Severely frail (7) N (%) 2 (2) 1 (2) 1 (1)
Medication prior to hospital admission
  Aspirin N (%) 113 (85) 52 (87) 61 (84) 0.81
  Statin N (%) 113 (85) 55 (92) 58 (79) 0.06
  Beta- blocker N (%) 94 (71) 42 (70) 52 (71) 1.00
  Calcium channel blocker N (%) 133 (100) 60 (100) 73 (100) 1.00
  Isosorbide mononitrate N (%) 50 (38) 20 (33) 30 (41) 0.38
  Nicorandil N (%) 47 (35) 22 (37) 25 (34) 0.86
  ACE inhibitor N (%) 101 (76) 50 (83) 51 (70) 0.10
  Insulin N (%) 20 (15) 10 (17) 10 (14) 0.64
  Oral antidiabetic therapy N (%) 28 (21) 10 (17) 18 (25) 0.29
  Antidepressant therapy N (%) 24 (18) 13 (22) 11 (15) 0.37
  Diuretic N (%) 52 (39) 18 (30) 34 (47) 0.07
Note that where there are missing values, the percentages are calculated out of the number of patients with data. Cardiac 
arrhythmia (2 missing from registry). New ischaemic ECG changes (1 missing from registry). Canadian Cardiovascular Society 
angina class (1 missing from trial, 1 missing from registry). Saphenous vein graft (2 missing from trial, 5 missing from registry).
Mean ± SD or median (IQR) for normal and non- normally distributed data, respectively.
*During the index hospitalisation, all patients in the randomised trial group had a type 1 MI, while seven patients in the 
registry group did not have a type 1 MI but had a type 2 MI (2 AF, 1 AF+HF, 1 severe aortic stenosis+HF, 1 anaemia, 1 
AF+acute kidney injury, 1 HF+respiratory tract infection).
†Diabetes mellitus was defined as a history of diet- controlled or treated diabetes.
‡Any previous episode with new ischaemic ECG changes.
§The highest Canadian Cardiovascular Society value of any previous episode for each patient.
ACE, Angiotensin- converting enyzme; AF, atrial fibrillation; HF, heart failure; MI, myocardial infarction.
Table 1 Continued
 on M
















Defined as postrandomisation rate of major adverse 
events (coprimary composite outcome), including one 
composite outcome for efficacy and one composite 
outcome for safety.
Primary efficacy outcome
Defined as all- cause mortality, rehospitalisation for refrac-
tory ischaemia/angina, MI or hospitalisation for HF. The 
endpoints were assessed during the study until the final 
randomised patient had completed 18 months follow- up.
Primary safety outcome
Defined as bleeding (Bleeding Academic Research 
Consortium (BARC) types 2–4),22 stroke, procedure- 
related MI (type 4a, universal definition), worsening 
renal function or haemodialysis during the index hospi-
talisation.
Secondary outcomes
1. Quality of life.
2. CCS angina class.
3. Hospitalisation for refractory ischaemia and/or angi-
na.
4. Repeat invasive management during follow- up.
5. Freedom from coronary and/or bypass graft 
intervention.
Definitions of adverse events
Refractory ischaemia, death, procedure- related MI, 
stroke, major bleeding and worsening renal function are 
defined in online supplemental methods.
RESULTS
Two hundred and seventeen patients with prior CABG 
and an unplanned hospitalisation for a suspected 
NSTE- ACS were screened (figure 1).
Eighty- four (39%) participants were identified during 
screening but were deemed ineligible for progressing into 
the trial or registry, of whom 24 (29%) did not consent 
and 60 (71%) consented but were ineligible (≥1 reason): 
42 (70%) not confirmed NSTE- ACS, 39 (65%) not stabi-
lised symptoms, 4 (7%) no prior CABG, 5 (8%) refractory 
ischaemia, 3 (5%) unable to provide informed consent 
and 22 (37%) unsuitable for invasive management.
Of 133 (61%) eligible patients who consented to either 
the trial or registry, 60 patients (mean±SD age, 71±9 years, 
43 (72%) male) were randomised and 73 (mean±SD age, 
72±10 years, 53 (73%) male) entered the registry. The 
decision for entering the registry included physician 
preference (58 (79%)), patient preference (28 (38%)) 
or both (15 (21%)).
Baseline characteristics
The characteristics of the trial and registry participants 
are described (table 1). Compared with trial participants, 
registry patients were twice as likely to have valve disease 
(31 (42%) vs 12 (20%); p=0.01), a lower haemoglobin 
(mean±SD 127±18 vs 135±16 g/L; p=0.01), worse New 
York Heart Association class (37% vs 20% in class III or IV; 
p=0.01) and higher frailty index (27% vs 18% moderately 
or severely frail and 38% vs 23% mildly frail; p=0.03). Fifty 
(83%) trial and 59 (81%) registry patients participants had 
a previous left internal mammary artery graft (p=0.82). 
Baseline EQ- VAS, EQ- 5D- 5L and medications were similar.
In-hospital clinical course and invasive management
More than twice as many patients in the registry versus 
the trial had a medication change for recurrent angina. 
Approximately three- quarters of registry patients 
had medication changes for standard optimisation 
of secondary prevention therapy compared with trial 
patients (table 2).
At baseline, invasive management (coronary angiog-
raphy±PCI) was undertaken in 31 (52%) and 36 (49%) 
patients in the trial and registry groups, respectively, 
increasing during follow- up to 46 (77%) and 40 (55%), 
respectively (table 3). Of those who had invasive manage-
ment at baseline and follow- up, PCI was performed in 10 
(22%) and 13 (33%) of trial and registry patients at base-
line, increasing to 21 (46%) and 18 (45%) patients during 
follow- up, respectively (table 3). For baseline procedures, 
the British Cardiovascular Intervention Society-1 Jeop-
ardy Score was similar between trial (4±4) and registry 
(5±3; p=0.19) patients (table 3). At baseline and follow- up, 
compared with trial patients, registry patients had more 
urgent inpatient invasive procedures (39 (75%) vs 27 
(47%)) and fewer outpatient invasive procedures (13 
(25%) vs 30 (53%); p=0.004) (table 3). The culprit lesion 
was uncertain in 27 (47%) and 21 (40%) of procedures 
in the trial and registry groups, respectively (table 3). 







N=73 (%) P value
Recurrent angina 47 (35) 13 (22) 34 (47) 0.003
Standard optimisation of secondary prevention therapy 103 (77) 54 (90) 49 (67) 0.002
Intolerance of therapy without adverse reaction 8 (6) 2 (3) 6 (8) 0.293
Adverse drug reaction 10 (8) 2 (3) 8 (11) 0.113
Other 7 (5) 3 (5) 4 (5) 1.000
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Adoption of adjunctive techniques, for example, rotational 
atherectomy was low (table 3).
Health outcomes
During a median of 694 (IQR 558–841) days follow- up, 
the primary efficacy outcome occurred in 26 (43%) and 
36 (49%) trial and registry participants, respectively (HR 
1.14, 95% CI 0.69 to 1.89) (table 4). The primary safety 
outcome occurred in 17 (28%) and 16 (22%) trial and 
registry participants, respectively (HR 0.74, 95% CI 0.37 to 
1.46). The observed proportion of registry patients experi-
encing the efficacy outcome was slightly higher than in the 
trial group, whereas the opposite occurred for the safety 
Table 3 Invasive management (coronary angiography±PCI) in trial and registry patients at baseline (index admission) and 
follow- up (≥18 months)




N=40 (%) P value
  Patients with one procedure 37 (80.4) 32 (80.0) 0.084
  Patients with two procedures 8 (17.4) 4 (10.0)
  Patients with three procedures 0 (0) 4 (10.0)
  Patients with four procedures 1 (2.2) 0 (0)
  Patients with PCI at baseline 10 (21.7) 13 (32.5) 0.331
  Patients with PCI at baseline and follow- up 21 (45.7) 18 (45.0) 1.000
Days from enrolment to patient’s first procedure 22.5 (6.5-64.75) 1.5 (0-7.25) <0.001
  <30 days 25 (54.3) 36 (90.0) <0.001
  30–59 days 9 (19.6) 0 (0)
  ≥60 days 12 (26.1) 4 (10.0)





  BCIS Jeopardy Score (pre- PCI) at baseline* 4.3±3.7 5.4±3.1 0.189
  PCI at baseline 10 (32.3) 13 (36.1) 0.800
  BCIS Jeopardy Score (post- PCI) at baseline 2.4±2.5 4.0±3.4 0.220





  Urgent in- patient procedure 27 (47.4) 39 (75.0) 0.004
  Outpatient procedure 30 (52.6) 13 (25.0)
  Hospitalisation† 28 (49.1) 41 (78.8) 0.002
  Complications related to angiogram‡ 1 (1.8) 6 (11.5) 0.052
  Culprit vessel uncertain 27 (47.4) 21 (40.4) 0.563
  Culprit vessel identified 30 (52.6) 31 (59.6)
  Graft only 17 (56.7) 15 (48.4) 0.611
  Native artery only 12 (40.0) 15 (48.4) 0.609
  Both graft and native artery 1 (3.3) 1 (3.2) 1.000
  Multiple culprit lesions 3 (10.0) 2 (6.5) 0.671
  PCI at baseline and follow- up 24 (42.1) 25 (48.1) 0.567
  Thrombus aspiration 1 (4.2) 0 (0) 0.490
  Rotational atherectomy 4 (16.7) 0 (0) 0.050
  Intravascular ultrasound 2 (8.3) 3 (12.0) 1.000
  Distal protection device 3 (12.5) 2 (8.0) 0.667
Mean±SD and median (IQR) for non- normally distributed data.
*BCIS Jeopardy score not available in one registry patient because of poor- quality angiogram and limited data for right coronary artery (only 
still frame and not a run).
†Admission to hospital including at least one overnight stay.
‡Complications in trial (N=1) was worsening renal function after angiography; complications in registry (N=6) were side branch abrupt 
closure, main branch distal embolisation into filter, no reflow, dissection post- angioplasty (+haematoma > 5 cm in same patient), pulmonary 
oedema on angiography table, side branch new/worsened thrombus.
BCIS, British Cardiovascular Intervention Society; PCI, percutaneous coronary intervention.
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HR (registry vs trial)
(95% CI)
Primary efficacy outcome
Composite of all- cause mortality, rehospitalisation for refractory ischaemia/angina, MI and HF 26 (43%) 36 (49%) 1.14 (0.69 to 1.89)
Primary safety outcome
Composite of bleeding (BARC≥2), stroke, procedure- related MI and worsening renal function 
during the index hospitalisation
17 (28%) 16 (22%) 0.74 (0.37 to 1.46)
Experienced both primary efficacy and safety outcomes 10 (17%) 8 (11%) 0.64 (0.25 to 1.63)
Experienced either primary efficacy or safety outcomes 33 (55%) 44 (60%) 1.05 (0.67 to 1.65)
Components of primary efficacy outcome
All- cause mortality 8 (13%) 17 (23%)
Cardiovascular death 2 (3%) 10 (14%)
Non- cardiovascular death 4 (7%) 5 (7%)
Unknown cause of death 2 (3%) 2 (3%)
Rehospitalisation for refractory ischaemia/angina 0 (0%) 0 (0%)
Non- fatal MI 22 (37%) 18 (25%)
HF 7 (12%) 11 (15%)
Primary efficacy outcome at 12 months
Composite of all- cause mortality, rehospitalisation for refractory ischaemia/angina, MI and HF 
at 12 months
20 (33%) 23 (32%)
All- cause mortality at 12 months 5 (8%) 9 (12%)
Components of primary safety outcome
Bleeding (BARC 2–4) 11 (18%) 10 (14%)
Stroke 0 (0%) 2 (3%)
Procedure- related MI 0 (0%) 0 (0%)
Worsening renal function during the index hospitalisation 8 (13%) 5 (7%)
Primary safety outcome at 12 months
Composite of bleeding (BARC≥2), stroke, procedure- related MI and worsening renal function 
during the index hospitalisation at 12 months
12 (20%) 14 (19%)
Other secondary outcomes
Total number of SAE 170 117
Number of patients with a SAE 40 (67%) 49 (67%)
Number of SAEs per patient, median (IQR) 1(0, 2) 1(0, 2)
Number of patients experiencing
Rehospitalisation 39 (65%) 47 (64%)
Invasive management (coronary angiography) 46 (77%) 40 (55%)
PCI 21 (35%) 18 (25%)
Redo CABG 0 (-) 1 (1%)
Coronary revascularisation (PCI or CABG) 21 (35%) 18 (25%)
Quality of life and angina
EQ- VAS health status, 6 months, median (IQR) 75 (60-80) 50 (40-75)
EQ- 5D- 5L score, 6 months, median (IQR) 0.82 (0.53-0.94) 0.61 (0.29-0.82)
CCS angina class, 6 months, median (IQR) 3.0 (1.0-3.0) 3.0 (2.0-4.0)
EQ- VAS health status, 12 months, median (IQR) 70 (50-80) 58 (40-75)
EQ- 5D- 5L score, 12 months, median (IQR) 0.82 (0.62-0.95) 0.78 (0.50-0.89)
CCS angina class, 12 months, median (IQR) 3.0 (3.0-4.0) 3.0 (2.0-4.0)
HRs and corresponding 95% CI from an unadjusted Cox model are given for the time from study entry to occurrence of primary outcomes only, comparing the 
registry to the trial group. Median (IQRs) are used for non- normally distributed data. Follow- up period was over median 694 (IQR 558–841) days.
BARC, Bleeding Academic Research Consortium; CABG, coronary artery bypass graft; CCS, Canadian Cardiovascular Society; EQ- 5D- 5L, EuroQol 5 Dimensions 5 
Levels; EQ- VAS, EuroQol Visual Analogue Scale; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; SAE, serious adverse event.
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outcome. When considered together (efficacy or safety), 
the rates were very similar between the groups. There was 
a lower proportion in the registry group experiencing both 
outcomes, but these events were very small in number.
Kaplan- Meier survival curves (figure 2) reveal that 
health outcomes in the trial and registry groups were 
similar during follow- up. Compared with the trial group, 
all- cause mortality and cardiovascular death occurred 
more often in the registry group, but non- fatal MI and 
worsening renal function during the index hospitalisa-
tion occurred less often (table 4). Two- thirds of patients 
in both groups experienced a serious adverse event 
(table 4). Redo CABG occurred in only one registry 
patient and in none of the trial participants (table 4).
Health status
Compared to the trial group, the median EQ- VAS health 
status in the registry group was 25 points lower (worse) 
at 6 months, and 12 points lower at 12 months (table 4).
Angina
The CCS angina class was similar between the groups at 
6 months (median (IQR) trial 3 (1-3) vs registry 3 (2-4)) 
and 12 months (median (IQR) trial 3 (3-4) vs registry 3 
(2-4)) (table 4).
DISCUSSION
The main findings of our study are, compared with the 
trial group, in the registry group: (1) multimorbidity, func-
tional limitation, frailty and impaired health status were 
more pronounced; (2) changes to medication were more 
often made because of recurrent angina but less often 
made for standard optimisation of secondary prevention; 
(3) in invasively managed patients, the extent of jeopard-
ised myocardium was similarly high and the culprit lesion 
was identified in half, and revascularisation by PCI was 
performed on one third; (4) health- related quality of 
life was lower at baseline, 6 and 12 months and (5) there 
was a fourfold increased risk of cardiovascular death, 
although power was limited. Overall, our study provides 
novel, contemporary insights into an understudied sub- 
group of ACS patients with a substantial health burden.
Our registry- based trial provided a framework for 
information to be prospectively gathered on patients 
who may have been eligible for randomisation but were 
not, including the reasons for not being randomised. 
Registry participation reflected physician and/or patient 
preferences for one form of treatment over another.16 
These beliefs substantially limited enrolment into the 
randomised trial. This finding has implications for 
the design and funding of future trials in this popula-
tion. Moreover, the finding in the comparison of the 
Figure 2 Kaplan- Meier survival curves: during a median of 694 (IQR 558–841) days follow- up: (A) The primary efficacy 
outcome occurred in 26 (43%) and 36 (49%) of trial and registry participants, respectively, HR 1.14, 95% CI 0.69 to 1.89. (B) 
The primary safety outcome occurred in 17 (28%) and 16 (22%) of trial and registry participants, respectively, HR 0.74, 95% CI 
0.37 to 1.46. (C) The primary efficacy and safety outcome occurred in 10 (17%) and 8 (11%) of trial and registry participants, 
respectively, HR 0.64, 95% CI 0.25 to 1.63. (D) The primary efficacy or safety outcome occurred in 33 (55%) and 44 (60%) of 
trial and registry participants, respectively, HR 1.05, 95% CI 0.67 to 1.65.
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Coronary artery disease
randomised trial groups that health outcomes were not 
different with invasive management versus conserva-
tive management supports the notion that enrolment 
rates could be increased by education of physicians 
and patients.21 Our trial results broadly reflect equi-
poise between the randomised strategies which should 
enhance confidence to support enrolment into a future 
randomised trial.
Compared with trial participation, registry participa-
tion was associated with a fourfold higher likelihood of 
cardiovascular death, with the caveat that event rates 
were very low for this outcome. This prognostic associ-
ation may be partly explained by the greater burden of 
cardiovascular health problems at baseline, including HF 
and valve disease. Compared with trial patients, registry 
patients had more medication changes for recurrent 
angina—this may be partly explained by some registry 
patients having symptoms which were not stabilised and/
or refractory ischaemia (both reasons for exclusion from 
the randomised trial) (figure 1). However, up- titration 
of medical therapy for secondary prevention occurred 
less often in the registry group, implying less intensive 
management, less scope for therapy improvements 
or both. The results highlight the substantial levels of 
morbidity, polypharmacy and adverse health outcomes in 
this group. The clinical course of two participants is illus-
trated (online supplemental figures 1 and 2).
Advances in interventional management
In our trial, invasive management was selected in 36 
(49%) of registry participants at baseline, but PCI was 
performed in only 13 (36%) of these patients. The lower 
PCI rate in our population may be explained by the 
complex nature of native vessel and graft disease, lack 
of a clear culprit (in almost half), and, arguably, lack of 
definitive evidence in support of the benefits of PCI in 
this population.
PCI continues to evolve with technical advances poten-
tially leading to improvements in safety and procedural 
success (online supplemental discussion).
Feasibility of a future substantive trial in patients with an 
NSTE-ACS and prior CABG
About one in 10–15 NSTE- ACS patients have a prior 
CABG (online supplemental table 1).6 This proportion 
is likely to remain stable in the coming years reflecting 
revascularisation practices in the past decade and 
increasing longevity. Many participants in this study were 
elderly, frail and multimorbid. Screening and obtaining 
informed consent were time- consuming for research 
staff. Medical decisions during urgent care may happen 
out- with office hours when research staff availability was 
limited. Medical information was commonly lacking at 
the time of hospitalisation, for example, graft history, 
limited recall by patients. These considerations present 
logistical barriers to enrolling patients into a randomised 
trial.
High event rates in patients with an NSTE-ACS and prior CABG
Almost half of the participants in both groups expe-
rienced a primary efficacy outcome event (table 4). 
In contemporary trials involving NSTE- ACS patients, 
the 12- month major adverse cardiac event (MACE) 
rate is usually 8%–10%, which is very much lower than 
observed in this study’s patients. The proportion of 
affected patients increased substantially during longer- 
term follow- up beyond 12 months. Again, this progressive 
accrual of adverse cardiac events over time contrasts with 
other trials in NSTE- ACS patients in which cardiac events 
may plateau over time. The older age and universal 
presence of multi- morbidity probably explain the differ-
ences in prognosis between NSTE- ACS patients with 
versus without prior CABG. Considering future trials in 
NSTE- ACS patients with prior CABG, there are consider-
able logistical challenges to enrolment but, however, the 
event rate implies that the sample size may be lower than 
for other populations in which primary outcome event 
rates are expectedly lower.
Limitations
Our pilot trial was not powered to assess for between- 
group differences in the rates of the serious adverse 
events contributing to the prespecified efficacy and safety 
outcomes. The sample size was small, with resultant wide 
confidence intervals. Both groups included patients 
that were managed differently (PCI vs medical therapy), 
thereby confounding between- group comparisons.
CONCLUSION AND POTENTIAL VALUE OF RESULTS
Since clinical trials usually excluded patients with prior 
CABG, practice guidelines are not evidence based with 
respect to this group. In real- world practice, clinicians 
lack relevant information to inform decision making. 
Our trial and registry may be helpful in the design of clin-
ical trials in this patient group.
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SUPPLEMENTAL MATERIAL 1 
Supplemental Methods 2 
Setting 3 
Study participants were enrolled in two large urban hospitals and two regional district general 4 
hospitals in the National Health Service (NHS) in the United Kingdom (UK). The hospitals 5 
differed in geography, availability of catheter laboratory facilities on-site (or not), and hospital 6 
type (academic vs. regional). Royal Blackburn Hospital was the only hospital with an on-site 7 
cardiac catheterisation laboratory. In the other hospitals, patients were triaged for invasive 8 
management by referral and transferred to the regional cardiothoracic centre (Golden Jubilee 9 
National Hospital). 10 
Screening 11 
The clinical research team on each site screened for patients aged ≥18 years, of either sex, 12 
admitted during unscheduled emergency care with a suspected acute non-ST segment elevation 13 
acute coronary syndrome and prior coronary artery bypass graft (CABG). Screening took place 14 
in the acute medical and cardiology wards during the course of routine healthcare. Patients 15 
eligible for either invasive (with coronary and graft angiography) or non-invasive management 16 
were invited to participate. Eligible patients were given an information sheet prior to 17 
participation. All randomised and registry patients provided written informed consent as soon as 18 
feasible after hospital admission and prior to referral for coronary angiography. Each patient was 19 
given a site and study number and entered into a screening log which only contained de-20 
identified information. Patients who did not consent were included in the „screen failure‟ log. 21 
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2 
The community health index (CHI) or NHS number was recorded to enable electronic record 22 
linkage. 23 
Randomisation 24 
Randomisation was stratified by centre, using randomised permuted blocks of length 4 and 6, 25 
with block lengths chosen at random. 26 
Non-invasive group 27 
Participants who had been randomised to the non-invasive group could be referred for invasive 28 
management if any pre-specified criteria were met (Supplemental Methods). 29 
Invasive group 30 
Invasive management was performed early (i.e. ≤72 hours wherever possible) after hospital 31 
admission. Invasive management included native coronary and bypass graft angiography and 32 
coronary and/or graft revascularisation with percutaneous coronary intervention (PCI) and/or 33 
CABG, as clinically appropriate. 34 
Optimal medical therapy 35 
Optimal medical therapy was intended for all of the participants. Guidance on up-titration of 36 
medical therapy was provided in an investigator guideline. Medical therapy included dual anti-37 
platelet, anti-thrombotic, and anti-ischaemic therapies as per local protocols and international 38 
guidelines.[1,2] 39 
Non-invasive group 40 
Study participants who had been randomised to the non-invasive group could be referred for 41 
invasive management if one of the following pre-specified criteria are met: 1) recurrent or 42 
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refractory (class III or IV) angina with documented ischaemic electrocardiogram (ECG) changes 43 
whilst on “optimal” anti-ischaemic therapy, 2) new ST-segment elevation in two contiguous 44 
leads without Q waves or T wave inversion greater than 3 mm or development of haemodynamic 45 
instability, or 3) a deterioration in heart failure (HF) status (consistent with Killip class 3 or 4) 46 
that the attending clinician judges to be ischaemia-related based on the presence of symptoms, 47 
ECG changes and cardiac biomarker elevation. 48 
Follow-up and outcome collection 49 
Clinical research nurses and clinicians who were independent of the study teams and aware of 50 
the group allocations supported enrolment and follow-up assessments on all sites. They 51 
prospectively gathered information on screening, recruitment, randomisation (to medical therapy 52 
or invasive management), crossover rates, and serious adverse events in patients with prior 53 
coronary artery bypass graft and a recent non-ST segment elevation acute coronary syndrome. 54 
Data will be held for up to 20 years to enable long-term follow-up analyses. Following 55 
randomisation, clinical assessments involved gathering information from standard-of-care 56 
clinical reviews (end of hospitalisation, 30-42 days and 1 year) and also from clinical contacts 57 
recorded in the patients‟ medical records. In West of Scotland hospitals, a single system of 58 
electronic patient records is used for all hospital attendances and correspondence with primary 59 
care. 60 
Serious adverse events during the index admission and follow-up were evaluated from review of 61 
patient records obtained during usual care, and electronic health databases, using the CHI and 62 
NHS number. All outcomes were prospectively entered into an electronic Case Report Form. 63 
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Clinical Event Committee 64 
The Clinical Event Committee (CEC) reviewed cases of interest to determine if they meet the 65 
criteria defined in the pre-specified charter. Causality assessments were not made by the CEC. 66 
The CEC was blinded to all information relating to the randomisation group. The CEC included 67 
4 cardiovascular physicians who have expertise in the diagnosis and treatment of cardiovascular 68 
disorders and in the medical aspects of clinical trials. The CEC had a Chairman (M.C.P.) and 69 
coordinator (M.M.Y.L.) to assist with preparation of de-identified source clinical data, reports 70 
and communication with the Trials Unit. The CEC followed a pre-determined adjudication 71 
charter. 72 
Definitions of adverse events 73 
Refractory ischaemia 74 
Recurrent ischaemic symptoms lasting more than 5 minutes, whilst on optimal medical therapy 75 
(at least 2 anti-anginal treatments) with documented characteristic ECG changes indicative of 76 
ischaemia and requiring an additional intervention. An additional intervention was defined as 77 
reperfusion therapy for myocardial infarction (MI), cardiac catheterisation, and insertion of intra-78 
aortic balloon pump or revascularisation procedure (percutaneous coronary intervention or 79 
coronary artery bypass graft surgery) within 48 hours of the onset of this episode. This definition 80 




All-cause, sudden cardiac death, death due to MI, death due to HF, death due to stroke, death due 83 
to extra-axial haemorrhage, death due to cardiovascular operation, death due to other 84 
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cardiovascular cause (e.g. infective endocarditis), presumed cardiovascular death (undetermined 85 
cause of death), non-cardiovascular death.[4] 86 
Procedure-related MI 87 
According to the Universal Definition of MI (Type 4b).[5] A post-procedure ECG was used to 88 
diagnose Q-wave vs. non-Q-wave MI. 89 
Stroke 90 
Defined as the presence of a new focal neurologic deficit thought to be vascular in origin, with 91 
signs or symptoms lasting more than 24 hours;[3] subdural haemorrhage. 92 
Major bleeding 93 
Defined according to the Bleeding Academic Research Consortium criteria.[6]
 
 94 
Worsening renal function 95 
Defined as deterioration in estimated Glomerular Filtration Rate ≥ 25% of baseline during the 96 
index admission. 97 
Crossover 98 
A crossover between groups was defined as a change of treatment strategy from invasive to non-99 
invasive management, or vice versa. In addition, we pre-defined crossover as occurring within 30 100 
days after randomisation. 101 
Sample Size 102 
Since CABG-ACS was an exploratory pilot trial, no sample size calculation was performed. The 103 
sample size was n=60 based on the number of participants projected to be enrolled in 4 hospitals 104 
within a 12–18 month period. We chose this number across different secondary care settings to 105 
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be broadly representative of the diversity in UK hospitals. The sample size was selected to 106 
enable the feasibility of randomisation, and the reasons for not being randomised were 107 
prospectively recorded. The trial was designed but not powered to assess for between-group 108 
differences in the rates of the serious adverse events contributing to the prespecified efficacy and 109 
safety outcomes. 110 
Data management and biostatistics 111 
The Robertson Centre for Biostatistics acted as an independent coordinating centre for data 112 
management and statistical analyses. The Centre is registered with a Clinical Trials Unit 113 
(National Institute for Health Research Registration number: 16). The Chief Investigator 114 
(Professor Berry) had full access to all the data in the study and takes responsibility for its 115 
integrity and the data analysis. 116 
Patient confidentiality 117 
Patients were assigned an identification code at the time of recruitment. 118 
Statistical analysis 119 
Baseline data 120 
Baseline characteristics were summarised using mean (standard deviation (SD)) or median 121 
(interquartile range (IQR) for skewed data) for continuous variables, and count (%) for 122 
categorical variables. Baseline characteristics for randomised vs. registry participants were 123 
compared using t-tests, Mann-Whitney tests and chi-squared tests (or Fisher's exact tests) as 124 
appropriate. 125 
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Efficacy and safety outcomes 126 
Numbers of events and numbers (%) of patients with adverse events were summarised. The 127 
proportion of patients with adverse events was compared between the registry and trial groups 128 
with a chi-squared test. Kaplan-Meier curves were produced for time to occurrence of the 129 
primary efficacy and safety outcomes. The hazard ratios (HR) of the primary outcomes, 130 
comparing the registry to trial group, were calculated with corresponding 95% confidence 131 
interval (CI) from a Cox model. Secondary outcomes were presented as descriptive statistics 132 
only, since this was a pilot trial with insufficient power for statistical testing of these outcomes. 133 
Ethics 134 
Potential benefits to participants include avoidance of harmful invasive management and 135 
avoidance of longer-term stent failure. No additional interventions were proposed nor were 136 
procedures withdrawn that would be needed on clinical grounds. While the intention-to-treat in 137 
each group was either with non-invasive or invasive management, all treatment options remained 138 
available according to patient and physician preference i.e. patients initially randomised to 139 
medical therapy could have undergone invasive management and vice versa. 140 
Trial management 141 
A Trial Management Group including the researchers and Local Principal Investigator on each of 142 
the 4 sites coordinated the study‟s activities on a day-to-day basis. The NHS Sponsor monitored 143 
the trial. Since the trial was a pilot, there was no Independent Data and Safety Monitoring 144 
Committee. 145 
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Supplemental Discussion 146 
Pivotal trials excluded patients with prior CABG, limiting the applicability of practice guidelines 147 
that recommend invasive management in non-ST segment elevation acute coronary syndrome 148 
(NSTE-ACS) with prior CABG.[1,2,7] Our results provide real-world insights into the baseline 149 
characteristics, treatment and outcomes of patients who were ineligible for randomisation but 150 
provided informed consent for registry participation. Commonly, this information is not gathered 151 
in clinical trials due to resource implications and logistics. Bypass Angioplasty Revascularization 152 
Investigation (BARI) was a trial of percutaneous transluminal coronary angioplasty (PTCA) 153 
versus CABG.[8] BARI included a registry of eligible patients who were not randomised based 154 
on physician and/or patient preference.[8] The main reason for not being randomised was 155 
physician and patient preference for PTCA. In BARI, the physicians selected PTCA rather than 156 
CABG for 65% of registry patients who underwent revascularisation without compromising 157 
long-term survival either in the overall population or in patients with treated diabetes. This result 158 
is in contrast to the randomised trial where patients with treated diabetes who underwent CABG 159 
gained a survival advantage compared to those patients with treated diabetes who had PTCA. 160 
We also gathered information on the selection process for trial participation, providing insights 161 
into the reasons for this decision. Within the registry, invasive management was substantially the 162 
preferred strategy by physicians and cardiologists. However, the proportions of patients treated 163 
by PCI in the registry group and the invasive group in the randomised trial were similarly low. A 164 
registry can disclose information on patient subsets in whom an intervention may have 165 
differential effects (harm or benefit). 166 
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Registry patients who were selected for invasive management may have been identified by 167 
clinicians as being potentially amenable to gaining symptomatic or prognostic benefit from 168 
revascularisation. Conversely, registry patients who were selected for medical management may 169 
have been judged as having little to gain and at risk of harm from invasive management and with 170 
non-modifiable chronic health impairment. 171 
Advances in interventional management 172 
In recent years, radial artery access has become the standard approach for invasive management 173 
rather than femoral artery access. The left radial artery can provide arterial access in patients 174 
with a left internal mammary graft. However, Complete High risk Indicated Patient (CHIP) 175 
procedures may require simultaneous left and right coronary artery access which necessitates 176 
vascular access via the femoral artery. Overall, our results support the safety of invasive 177 
management in selected NSTE-ACS patients with prior CABG. 178 
Advances in CHIP procedures lead to new possibilities for revascularisation in patients with 179 
complex disease.[9] Specialist techniques have developed with „antegrade‟ and „retrograde‟ 180 
approaches to recanalize chronic totally occluded (CTO) coronary arteries such that CTO PCI in 181 
native vessel CTOs has become increasingly feasible.[9] However, CTO PCI procedures are 182 
complex, require advanced skills, only undertaken by a minority of interventional cardiologists, 183 
and are usually pre-planned on an elective basis. Equipment can be expensive. Some of these 184 
techniques evolved very recently and so were not routinely implemented in the invasively 185 
managed patients. Whether CHIP procedures would increase revascularisation rates, comparable 186 
safety, and improvements in prognosis merit prospective evaluation in a substantive multicentre 187 
trial.[9] 188 
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Abbreviations: Acronyms of trials 189 
FRISC II = FRagmin and Fast Revascularisation during InStability in Coronary artery disease 190 
ICTUS = Invasive versus Conservative Treatment in Unstable Coronary Syndromes 191 
ISAR-COOL = Intracoronary Stenting with Antithrombotic Regimen Cooling-Off 192 
LIPSIA-NSTEMI = The Leipzig Immediate versus early and late PercutaneouS coronary 193 
Intervention triAl in NSTEMI 194 
MATE = Medicine versus Angiography in Thrombolytic Exclusion 195 
MOSCA = coMOrbilidades en el Síndrome Coronario Agudo 196 
OASIS-5 = Fifth Organization to Assess Strategies in Ischemic Syndromes 197 
RINCAL = Revascularisation or Medical Therapy in Elderly Patients with Acute Anginal 198 
Syndromes 199 
RITA 3 = Randomized Intervention Trial of unstable Angina 200 
TACTICS-TIMI 18 = Treat Angina with Aggrastat and Determine Cost of Therapy with an 201 
Invasive or Conservative Strategy – Thrombolysis in Myocardial Infarction 18 202 
TIMACS = Timing of Intervention in Acute Coronary Syndromes 203 
TIMI IIIB = Thrombolysis in Myocardial Ischemia 204 
TRUCS = Treatment of Refractory Unstable angina in geographically isolated areas without 205 
Cardiac Surgery 206 
VANQWISH = Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital 207 
VINO = Value of first day angiography/angioplasty In evolving Non-ST segment elevation 208 
myocardial infarction: an Open multicenter randomized trial 209 
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Supplemental Tables 210 
Supplemental Table 1. Trials of patients with non-ST elevation acute coronary syndromes. 211 




N N (%) with prior CABG 
   VANQWISH[10] 1998 920 156 (17.0%) (CABG >3 months before randomisation) 
   MATE[11] 1998 201 19 (9.5%) 
   TRUCS[12] 2000 148 18 (12.2%) 
   TACTICS-TIMI 18[13] 2001 2220 484 (21.8%) (CABG >6 months before randomisation) 
   ISAR-COOL[14] 2003 410 48 (11.7%) 
   ICTUS[15] 2005 1200 105 (8.8%) 
   OASIS-5[16] 2009 20078 1643 (8.2%) 
   Italian Elderly ACS[17] 2012 313 29 (9.3%) 
   LIPSIA-NSTEMI[18] 2012 600 41 (6.8%) 
   CABG-ACS pilot[19,20] 2016 60 60 (100.0%) 
   After Eighty study[21] 2016 457 76 (16.6%) 
   MOSCA[22] 2016 106 14 (13.2%) 





   TIMI IIIB[23] 1994 1473 CABG at any time 
   FRISC-II[24] 1999 2457 Previous open-heart surgery 
   VINO[25] 2002 131 CABG less than 6 months 
   RITA 3[26] 2002 1810 CABG at any time 
 212 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Open Heart
 doi: 10.1136/openhrt-2020-001453:e001453. 8 2021;Open Heart, et al. Lee MMY
12 
Supplemental Figures 213 
Supplemental Figure 1. 214 
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Supplemental Figure Legends 216 
Supplemental Figure 1: 217 
Clinical case example: This 72-year-old male in the registry had an inpatient coronary angiogram 218 
at baseline which showed a (A) blocked right coronary artery (red arrow) and a (B) tight stenosis 219 
in his saphenous vein graft supplying the obtuse marginal artery (orange arrow). He underwent 220 
(C) successful percutaneous coronary intervention to this saphenous vein graft (yellow arrow), 221 
thereby restoring flow to his (D) right coronary artery (green arrow) which was collateralised by 222 
his circumflex artery. This case highlights a diseased culprit vessel supplying collaterals to 223 
another territory that is not supplied by another patent saphenous vein graft or native artery. This 224 
participant experienced serious adverse events during follow-up including bleeding (Bleeding 225 
Academic Research Consortium type 2) and heart failure hospitalisation. 226 
 227 
Supplemental Figure 2: 228 
Clinical case example: This 63-year-old male with a history of previous coronary artery bypass 229 
grafting and multiple coronary stents for intractable angina, was admitted with a non-ST 230 
elevation acute coronary syndrome and was recruited to the CABG-ACS registry due to 231 
physician preference for invasive management. Urgent inpatient coronary angiography revealed 232 
a (A) occluded native right coronary artery (red arrow) and (B) diseased saphenous vein graft-233 
right coronary artery (orange arrow). (C and D) Percutaneous coronary intervention to his 234 
saphenous vein graft-right posterior descending artery (yellow) was unsuccessful (plain old 235 
balloon angioplasty only, no stents). Following multi-disciplinary team discussion, he 236 
subsequently underwent redo coronary artery bypass grafting (long saphenous vein to posterior 237 
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descending artery) but unfortunately after a protracted post-operative recovery period, he did not 238 
survive. 239 
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